Characteristics and treatment regimens across ERS SHARP severe asthma registries
11 января 2021 года
05:45
Characteristics and treatment regimens across ERS SHARP severe asthma registries
Текст новости:
Title: Characteristics and treatment regimens across ERS SHARP severe asthma registries
Author, co-author: van Bragt, J. J. M. H.; Adcock, I. M.; Bel, E. H. D.; Braunstahl, G.-J.; ten Brinke, A.; Busby, J.; Canonica, G. W.; Cao, H.; Chung, K. F.; Csoma, Z.; Dahlén, B.; Davin, E.; Hansen, S.; Heffler, E.; Horvath, I.; Korn, S.; Kots, M.; Kuna, P.; Kwon, N.; Louis, Renaud; Plaza, V.; Porsbjerg, C.; Ramos-Barbon, D.; Richards, L. B.; Škrgat, S.; Sont, J. K.; Vijverberg, S. J. H.; Weersink, E. J. M.; Yasinska, V.; Wagers, S. S.; Djukanovic, R.; Maitland-Van der Zee, A. H.; Abenhardt, B.; Adler, J.; Alfonso, R.; Ali, R.; Alkameh, S.; Almonacid Sánchez, C.; Alvares, L.; Anderson, G.; Assing, K.; Ayre, S.; Becker, J.; Bergmann, K.; Bieksiene, K.; Bjerring, N.; Blasi, F.; Bloemen, P.; Blum, H.; Böing, S.; Bonavia, M.; Bossios, A.; Bourdin, A.; Brons, A.; Brusselle, G.; Buis, J.; Caiaffa, M.; Calabrese, C.; Camiciottoli, G.; Caruso, C.; Castilla Martínez, M.; Centanni, S.; Cisneros Serrano, C.; Corsico, A.; Cosmi, L.; Costantino, M.; Costello, R.; Crimi, N.; Dahlen, S.; D'Amato, M.; Davies, D.; de Borja García-Cosío Piqueras, F.; Decarlo, G.; Deimling, A.; Del Giacco, S.; Diaz Campos, R.; Djandji, M.; Doberer, D.; Dupont, Laura; Dyett, K.; Edelbaher, N.; Edelmann, M.; Ehmann, R.; Ekberg-Jansson, A.; Farsi, A.; Favero, E.; Feimer, J.; Fletcher, M.; Foschino, B.; Frankemölle, B.; Gaga, M.; Gappa, M.; García de Pedro, J.; García Rivero, J.; Gasplmayr, M.; Gebhardt, R.; Geldmacher, H.; Geltner, C.; Gerstlauer, M.; Gibson, T.; Giuseppe, G.; Gogoll, C.; Grimm-Sachs, V.; Grisle, I.; Grün, B.; Grünewaldt, A.; Guarnieri, G.; Gullón Blanco, J.; Hamelmann, E.; Hamerlijnck, D.; Hammers-Reinhard, A.; Hanon, S.; Harzheim, D.; Heaney, L.; Hellmich, S.; Herden, M.; Hering, T.; Herth, F.; Hilberg, O.; Howarth, P.; Hubatsch, M.; Humbert, M.; Husemann, K.; Idzko, M.; Jackson, D.; Jandl, M.; Jaumont, X.; Joos, G.; Jöst, M.; Jüch, M.; Kabesch, M.; Kaiser-Labusch, P.; Kardos, P.; Käßner, F.; Keeley, T.; Kerr, W.; Kirschner, J.; Klimek, L.; Koca, M.; Koczulla, R.; Koerner-Rettberg, C.; Kopac, P.; Kronsbein, J.; Kupryś Lipinska, I.; Langer, M.; Langeveld, B.; Lantz, A.; Lazarinis, N.; Lazic, Z.; Lehtimäki, L.; Leuppi, J.; Lombardi, C.; Lommatzsch, M.; López-Viña, A.; Luca, R.; Lúdvíksdóttir, D.; Lüttecke-Hecht, C.; Macchia, L.; Magni, T.; Martínez Rivera, C.; Mastoridis, P.; Mazza, F.; Menzella, F.; Menzies-Gow, A.; Michils, A.; Mihãlþan, F.; Milanese, M.; Milger-Kneidinger, K.; Molinska, J.; Montagna, I.; Montuschi, P.; Mülleneisen, N.; Muñoz Esquerre, M.; Nanzer-Kelly, A.; Nenasheva, N.; Neurohr, C.; Nucera, E.; Otker, J.; Oud, K.; Paggiaro, P.; Parente, R.; Parkinson, J.; Passalacqua, G.; Patberg, N.; Patella, V.; Patino, O.; Paulsson, T.; Peche, R.; Pelaia, G.; Peress, E.; Pérez de Llano, L.; Pfeffer, P.; Pfister, P.; Pilette, C.; Pinedo Sierra, C.; Pini, L.; Powitz, F.; Ranger, T.; Rasmussen, L.; Rasmussen, K.; Rezelj, M.; Ricciardi, L.; Ricciardolo, F.; Ridolo, E.; Rijssenbeek-Nouwens, L.; Rolla, G.; Romero Ribate, D.; Rüdiger, S.; Safioti, G.; Sandström, T.; Santus, P.; Sauer, R.; Schauerte, G.; Schipmann, R.; Schleich, Florence; Schmid, J.; Schmidt, F.; Schmidt, O.; Schmitz, M.; Schrag, T.; Schröer, S.; Schultz, K.; Schulz, C.; Scichilone, N.; Sedlak, V.; Selb, J.; Senna, G.; Sergejeva, S.; Serrano Pariente, J.; Sichau, M.; Simona, D.; Singer, A.; Skowasch, D.; Smeenk, F.; Smith, S.; Solidoro, P.; Spadaro, G.; Spanevello, A.; Stefansdottir, M.; Steinmetz, K.; Steiß, J.; Stephan, M.; Stieglitz, S.; Suhling, H.; Taube, C.; Tolga Yavuz, S.; Tudoric, N.; Ulrik, C.; van de Ven, M.; van den Elshout, F.; van Dyke, M.; van Nederveen-Bendien, S.; van Veen, I.; Vandenplas, O.; Velthove, K.; Vianello, A.; Vogelberg, C.; Wallén-Nielsen, E.; Wisskirchen, T.; Yacoub, M.; Yancey, S.; Zappa, M.; Zielen, S.; Zimmermann, C.; Zimmermann, R.; SHARP Clinical Research Collaboration
Abstract: Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals. This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases. Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively. The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries. Copyright © ERS 2020

Связанные объекты: #ERS (найти в новостях), #A (найти в новостях), #Adler (найти в новостях), #Fletcher (найти в новостях), #Jackson (найти в новостях), #Stephan (найти в новостях), #Hungary (найти в новостях).

Текст со страницы (автоматическое получение):
Characteristics and treatment regimens across ERS SHARP severe asthma registries
Language :
Abstract :
[en] Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals. This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases. Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m−2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively. The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries. Copyright © ERS 2020
Funders :
Permalink :
Автоматическая система мониторинга и отбора информации
Источник
Другие материалы рубрики
  10 января 2021 года
05:45
CA19.9 assays provide clinically different results for the patients